CARDIOTOXICIDAD POR TRASTUZUMAB PDF

Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial Neutropenia inducida por dosis terapéuticas de metronidazol intravenoso. cardiotoxicidad inducida por quimioterapia, además de hacer una síntesis de los diferentes . tion (anthracyclines, trastuzumab, tyrosine kinase inhibitors.

Author: Mezikus Kagajind
Country: Panama
Language: English (Spanish)
Genre: Spiritual
Published (Last): 10 June 2011
Pages: 50
PDF File Size: 6.78 Mb
ePub File Size: 8.9 Mb
ISBN: 344-4-83849-534-5
Downloads: 79389
Price: Free* [*Free Regsitration Required]
Uploader: Vudozilkree

The patient developed heart rhythm disturbances that lead to sudden death after slow intravenous infusion of doxorubicin.

There was a problem providing the content you requested

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Therefore, these drugs produce undesirable side effects and are toxic to those taking such medications 1. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.

Trastuzumab is a humanized monoclonal antibody that acts on human epidermal growth factor receptor-2 HER2in which its target is the subdomain IV of the extracellular region of HER2, being indicated in the treatment of breast cancer with high expression of HER2 and in the treatment of adenocarcinoma of the gastroesophageal or metastatic gastric junction with high expression of HER2.

The diagnosis and management of cardiovascular disease in cancer patients. Local anaesthetics do not affect protein kinase C function in intact neuroblastoma cells.

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. Services on Demand Article. This is a retrospective, quantitative and descriptive study based on the medical records of patients who used the monoclonal antibody Trastuzumab. Cardiotoxicity induced by tyrosine kinase inhibitors. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.

Cardiotoxicity induced by chemotherapy and antibody therapy. A cardiotoxicidade da ciclofosfamida pode apresentar-se de forma aguda ou subaguda 4. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Cardiotoxicity of cytotoxic drugs. The analysis of medical records sought data such as: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.

  LOS IMAGINARIOS SOCIALES BACZKO PDF

Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas

These are new drugs in the clinic, for this reason, there is very little information on trastzuumab side effects, although its mechanisms of action are very specific, these monoclonal antibodies are not free of side effects.

Cardiac dysfunction induced by novel targeted anticancer therapy: Risk factors for atrial fibrillation after lung cancer surgery: Doxorubicin administration by continuous infusion is not cardioprotective: Anderson Cancer Center experience.

Recomenda-se manter o paciente em normovolemia e utilizar com cautela anti-hipertensivos durante o tratamento cardiottoxicidad o bortezomibe. Exercise interventions during cancer treatment: After the retrospective analysis of the medical records, it was verified that of the 59 patients selected, only 24 met the established cardkotoxicidad.

Tolerability of first-line therapy for metastatic renal cell carcinoma. Risk of thrombosis with lenalidomide and its prevention with aspirin. Exerc Sport Sci Rev. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: Ewertz M, Jensen AB. Spanish pdf Article in xml format Article references How to cite this article Automatic translation Send this article by e-mail.

The established exclusion criteria were traztuzumab with other types of cancer that did not express the HER2 receptor, as well as smokers and patients who underwent antiestrogen therapy.

Immunotherapy presents as the great proposal of treatment of some neoplasias with a focus on the decrease of adverse reactions. Int J Lab Hematol. Treatment of malignant pericardial effusion. Crit Rev Oncol Hematol. Comparison of the incidences of cardiac arrhythmias, myocardial ischemia, and cardiac events in patients treated with endovascular versus open surgical repair of abdominal aortic aneurysms. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.

  ASSIMIL FRANCESE PDF

The results of surgery under general anesthesia in patients with lung cancer. Because they are specific target drugs, few studies are concerned with evaluating these adverse events, which often makes clinical care difficult.

Currently, one of the major stakes in the treatment of cancer is immunotherapy, which consists of stimulation of the immune system through the use of substances modifying the biological response, which may occur through the result of the antigen-antibody interaction or the mechanisms involved in the mediated immunity by cells 5.

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. These agents are gaining space in the treatment of some types of cancer, as is the case of Trastuzumab in the treatment of breast cancer, Cetuximab in the treatment of colorectal cancer and Rituximab in the treatment of lymphomas 3.

Reversible cardiotoxicity with tyrosine kinase inhibitors. Prospective, randomized trial comparing fluids and dobutamine optimization of oxygen delivery in high-risk surgical patients [ISRCTN]. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Cardiotoxicity of kinase inhibitors: With respect to clinical staging, Santos et al 8 demonstrated a greater number of patients with stage III and II, corroborating the data collected in this study, presenting 13 patients in stage III and 9 patients with stage II trastuzukab shown in figure 3.